Media headlines about NanoString Technologies (NASDAQ:NSTG) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NanoString Technologies earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.8601170592972 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern’s scoring:
- NanoString Technologies Inc (NSTG) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Morgan Stanley Trims NanoString Technologies (NSTG) Target Price to $12.00 (americanbankingnews.com)
- NanoString Technologies (NSTG) Issues Earnings Results, Beats Estimates By $0.08 EPS (americanbankingnews.com)
- NanoString Technologies Releases Fourth Quarter and Full Year 2017 Operating Results and Provides 2018 Outlook (finance.yahoo.com)
- NanoString Technologies (NSTG) Issues FY18 Earnings Guidance (americanbankingnews.com)
NanoString Technologies (NASDAQ:NSTG) traded down $0.04 during trading hours on Wednesday, hitting $6.97. The company’s stock had a trading volume of 844,443 shares, compared to its average volume of 217,985. The stock has a market capitalization of $172.49, a P/E ratio of -3.76 and a beta of 0.91. NanoString Technologies has a 12-month low of $5.87 and a 12-month high of $20.70. The company has a current ratio of 3.40, a quick ratio of 2.84 and a debt-to-equity ratio of 1.22.
A number of brokerages have recently weighed in on NSTG. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective (down previously from $13.00) on shares of NanoString Technologies in a research note on Thursday, March 8th. ValuEngine downgraded NanoString Technologies from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded NanoString Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. NanoString Technologies presently has a consensus rating of “Hold” and a consensus target price of $13.06.
WARNING: This story was originally posted by BBNS and is the property of of BBNS. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://baseballnewssource.com/2018/03/14/nanostring-technologies-nstg-earning-somewhat-favorable-news-coverage-study-finds/1925845.html.
About NanoString Technologies
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.